Emideltide (DSIP) for Sleep: What the Human Trials Showed, Where They Disagreed, and What Users Report

REVIEWED BY

Marcus Reinhardt — Chemical Researcher, Lead Analyst & Peptide Research Advisor

Marcus Reinhardt is a chemical researcher specializing in sustainable materials and advanced formulation science, with research experience in compound development and health optimization. He reviews all Peptide Insider educational content for scientific accuracy, strength of supporting evidence, and practical relevance. Editorial team.

Emideltide (DSIP) for sleep — what the human trials showed and what users report

Written by Marcus Reinhardt · Lead Analyst, Peptide Insider · LinkedIn

Evidence-first peptide coverage — every claim on this page is linked to its primary source and reviewed against our editorial policy

Citations verified against PubMed · Published: 2026-09-09 · Last updated: 2026-09-10

Emideltide is the pharmacological name for the peptide the research market sells as DSIP, delta sleep-inducing peptide, and it is the only “sleep peptide” on that market with a body of controlled human sleep studies behind it. Between 1981 and 1992, synthetic emideltide was infused into healthy volunteers and into chronic insomniacs in at least eight studies with polysomnography, several of them double-blind and placebo-controlled. The group that discovered it found that it normalized disturbed sleep without sedating; two independent groups found the effect weak or clinically insignificant; and measurements of the body’s own DSIP found it falls, rather than rises, at the moment of falling asleep. This page walks through those studies one by one, sets out exactly what changed in sleep architecture and how quickly, explains why the field never resolved the disagreement, and then compares the trial record with what people injecting or spraying it in 2026 describe. It reports what the trials administered; it does not recommend an amount, and Peptide Insider never does.

Quick Answer: Does Emideltide Improve Sleep?

In the discovering group’s trials, yes; in independent replication, barely. Slow intravenous infusion of 25–30 nmol/kg gave chronic insomniacs shorter sleep onset, fewer awakenings, higher sleep efficiency and slightly more REM, with “complete normalization” after four consecutive injections and sleep still normal three to seven months later in most of one small series (PMID 6689058, PMID 6391926). A Uruguayan double-blind crossover found the same directional changes but nothing significant against placebo, “of little clinical significance” (PMID 3583493); a Dutch double-blind trial found weak effects and concluded it was “not likely to be of major therapeutic benefit” (PMID 1299794). Everything positive was intravenous; there is no controlled human sleep trial of the subcutaneous or nasal forms people actually buy. Users report the same split: tracker-measured gains in deep and REM sleep from some, nothing at all from as many, and the occasional night of no sleep.

★The Documented Experience: Fourteen Insomniacs, Seven Nights, a Sleep Laboratory

The most complete picture of what emideltide does to a bad sleeper comes from fourteen middle-aged people with severe chronic insomnia who spent a week in a Basel sleep laboratory in the mid-1980s. Under placebo-controlled, double-blind conditions they received the peptide intravenously on seven successive nights, with full polysomnograms recorded at placebo baseline, at the start and end of treatment, and on a placebo night afterward, and with their daytime mood and mental performance tested before and after six injections. Their night sleep improved substantially with the first dose and further with repeated ones; the improvement held on the first placebo night after treatment stopped; and their sleep efficiency and daytime rest “reached the levels of normal controls.” Their daytime alertness and performance rose significantly as well.

Set beside it, the sixteen chronic insomniacs in the Netherlands who received the same weight-based dose on three afternoons in 1992, half of them a glucose placebo, are the other half of the story. Their sleep efficiency was higher and their sleep latency shorter on emideltide, and one measure of tiredness fell, but the investigators judged the differences weak, partly an artefact of a change in the placebo group, and found no change at all in how the patients themselves rated their sleep.

Sources: PMID 3622582, PMID 1299794. When we publish an individual account here, it will be a real person, named with permission. We don’t write fiction into this slot.

Research peptide vial

Looking for Lab-Tested Peptides?

Emideltide is a nine-amino-acid peptide that blood enzymes clear quickly, which makes purity and identity testing matter more than usual: a vial that is not what the label says will produce exactly the “no effect” that half of users report. Amino Club publishes batch COAs and third-party testing on every compound — get up to 30% off your first order.

Shop Amino Club →

Affiliate link — it doesn’t change what we report. All compounds sold strictly for non-human research use. Read our full Amino Club review.

In This Guide

Why a Peptide Has a Sleep Stage in Its Name

Emideltide is a nonapeptide, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, molecular weight about 849 (PMID 8689946, PMID 6145137). The Schoenenberger-Monnier group in Basel isolated it in 1977 from rabbit cerebral venous blood while hunting for a humoral sleep factor, and named it for the electroencephalographic effect it appeared to carry from one animal to another: delta sleep-inducing peptide (PMID 16539679). The 1984 review that consolidated the first decade of work reported that it induced mainly delta sleep in rabbits, rats, mice and humans, while in cats the effect fell more on REM sleep (PMID 6145137). “Emideltide” is its International Nonproprietary Name, the claim-free label regulators use; it is the name the FDA’s compounding advisory committee used in July 2026, and the one we use here. Our emideltide side effects page covers the naming, the tolerability record and the endocrine findings in depth; this page is about sleep.

The name carries a claim, and the claim was never fully cashed. No gene, precursor protein or receptor for DSIP has been found in fifty years, and the 2006 review that called the peptide “a still unresolved riddle” judged the hypothesis that it is a sleep factor “extremely poorly documented and still weak,” noting that in the reviewers’ own animal work certain synthetic analogues promoted slow-wave sleep but DSIP itself did not (PMID 16539679). A 2003 review of the biochemistry of non-REM sleep listed DSIP among four historical “transfer” sleep factors for which “a physiological sleep regulatory role, however, has not been determined” (PMID 12700031). None of that erases the human trials below. It does mean the human trials are the evidence, rather than an illustration of a mechanism everyone accepts.

The Human Sleep Trials, Study by Study

Every study in this table gave synthetic emideltide to people and measured sleep. The doses are the doses the investigators reported. We list them because a reader comparing a research-market vial to the literature deserves to know what the literature used; the amounts are not suggestions, and the route in every positive trial, slow intravenous infusion under medical supervision, is not one anyone reproduces at home.

Study Design and participants Administered Sleep outcome
Schneider-Helmert 1981 6 healthy volunteers (4 M, 2 F), double-blind crossover, extensive psychophysiological monitoring 25 nmol/kg, slow IV, morning Immediate sleep pressure; total sleep +59% (median) over 130 min vs placebo; that night, shorter sleep onset, less stage 1, better efficiency; no classic sedation
Schneider-Helmert & Schoenenberger 1981 6 middle-aged chronic insomniacs 25 nmol/kg IV, single dose before sleep Longer sleep, fewer interruptions, slightly more REM, effect lasting up to 6 h of night sleep; sleep effect began in the second hour, slight arousal in the first
Lancet 1981 (letter, RCT) Insomniacs, randomized Not in abstract Title: “Synthetic delta-sleep-inducing peptide improves sleep in insomniacs”
Schneider-Helmert & Schoenenberger 1983 Summary of five double-blind studies, single and repeated IV IV; slow injection “essential” Latency ~1 h, duration up to 20 h; “complete normalization of disturbed sleep” after four consecutive injections in insomniacs
Schneider-Helmert 1984 Review of two insomnia studies plus repeated-dosing work 25 nmol/kg before sleep; repeated; morning; twice daily Single dose improved sleep; repeated doses built up to normalization after four; morning injections still helped night sleep; two doses daily did not
Kaeser 1984 Open study, 7 severe insomniacs, follow-up 3–7 months Series of 10 injections Sleep normalized in 6 of 7 for the whole follow-up; mood and daytime performance improved
Schneider-Helmert 1986 18 chronic psychophysiological insomniacs, two age groups (29–59, 60–83), sleep laboratory 6 × 30 nmol/kg IV over one week Middle-aged: normal by end of the week, held through a follow-up week; elderly (twice the baseline disturbance): larger immediate effect, full normalization only by end of follow-up; effect size tracked severity
Schneider-Helmert 1987 14 middle-aged severe chronic insomniacs, placebo-controlled double-blind, polysomnography IV on 7 successive nights Substantial improvement with first and repeated doses; maintained on first post-treatment placebo night; efficiency reached normal-control levels
Monti 1987 Chronic insomniacs, double-blind crossover, polysomnography 25 nmol/kg IV, four nights Awakenings, NREM latency and waking time fell but not significantly vs baseline or placebo; total and NREM (stage 2) sleep rose, but the difference pre-existed at baseline; SWS and REM unchanged; “of little clinical significance”
Bes 1992 16 chronic insomniacs, double-blind matched-pairs parallel groups, 5 laboratory nights 25 nmol/kg IV in the afternoon before nights 3–5, vs glucose placebo Higher sleep efficiency and shorter latency on DSIP; one tiredness measure fell; effects “weak,” partly due to a change in the placebo group; subjective sleep quality unchanged; “not likely to be of major therapeutic benefit”

The pattern is not subtle. Every positive result came from the Basel group that discovered the compound, or from Kaeser’s open series published alongside its papers in the same 1984 issue of European Neurology. The two double-blind trials run elsewhere, in Uruguay in 1987 and the Netherlands in 1992, saw changes in the same direction and judged them clinically meaningless. That is a common shape in pharmacology, and it does not by itself decide who was right; the Basel trials used repeated nightly dosing and severe insomniacs, the independent trials used shorter courses. But it is the shape, and a reader should see it before reading the positive findings in detail.

What Changed in Sleep Architecture

Sleep trackers report “deep” and “REM” minutes, and users of emideltide report their trackers. The trials measured the same things with polysomnography. Here is what moved, measure by measure, in the studies that reported it.

Measure Finding Source
Sleep onset latency Shorter the night after a morning dose in volunteers; shorter vs placebo in insomniacs (weak); NREM latency fell non-significantly in Monti 6895513, 1299794, 3583493
Sleep efficiency Improved in volunteers; reached normal-control levels after a week in severe insomniacs; higher vs placebo in Bes 6895513, 3622582, 1299794
Awakenings / interruptions Fewer interruptions in insomniacs; awakenings and waking time fell non-significantly in Monti 7028502, 3583493
Stage 1 (lightest sleep) Reduced percentage the night after dosing in volunteers 6895513
Stage 2 Increased in Monti, accounting for the rise in total and NREM sleep, but the difference from placebo existed at baseline 3583493
Slow-wave sleep (stages 3–4, “deep”) Not modified in the one independent polysomnographic trial that reported it; the Basel abstracts describe “normalization of sleep structure” without giving stage figures 3583493, 6391925
REM sleep “Slightly more” in insomniacs; enhanced in the narcolepsy case; unchanged in Monti 7028502, 6548968, 3583493
Total sleep time +59% over 130 min after a morning dose in volunteers; longer night sleep in insomniacs; increased (stage 2) in Monti 6895513, 7028502, 3583493
Subjective sleep quality Higher quality reported in the 1981 insomnia study; no change in the 1992 double-blind trial 7028502, 1299794

The line to notice is the one for slow-wave sleep. A compound named for inducing delta sleep did not change slow-wave sleep in the one independent trial that measured and reported it, and the positive Basel abstracts, while they speak of normalized sleep structure, do not report a delta-sleep increase either. What they report is a more efficient, less interrupted, less shallow night. Users who describe a jump in their tracker’s “deep sleep” minutes are describing something the trials did not find, which does not make the users wrong about their trackers, but does mean the two are not measuring the same thing.

KEY TAKEAWAY

The trial evidence for emideltide is evidence for consolidation: falling asleep sooner, waking less, spending less of the night in the lightest stage. It is not evidence for more deep sleep, which is the thing its name promises and the thing most people buy it for. Anyone judging it by a deep-sleep number is judging it against a claim the trials never made.

How Fast It Acted and How Long It Lasted

Emideltide is not a hypnotic that knocks a person out, and the timing data are the clearest demonstration. In the 1981 insomnia study, “sleep-promoting effects occurred only in the second hour after injection, in the first hour a slight arousing effect was indicated” (PMID 7028502). The 1983 summary put the latency of sleep induction at about one hour and the duration of effect at up to 20 hours (PMID 6689058). That long tail is why the Basel group could inject volunteers in the morning and still see shorter sleep onset and better efficiency that night (PMID 6895513), and why the 1984 paper found that morning injections, besides raising daytime activity, “still had a strong positive effect on night sleep” (PMID 6391925).

The same paper contains the one timing finding that runs the other way: two doses daily did not work. Combined with the bell-shaped dose-response curves described in the 1984 review and the animal pharmacology (PMID 6145137, PMID 6548967), the picture is of a compound with a window: a single, slow, weight-based dose once a day, repeated on consecutive days, was what the positive trials used, and both halving the interval and pushing the dose seem to have lost the effect. The 1986 study’s finding that the effect built over a week, with elderly insomniacs needing until the end of a second week to reach normal sleep (PMID 3792404), is the trial-side counterpart to the user who wrote that DSIP “works, but requires patience.”

Who Responded: Severity, Age and the Build-Up Effect

The 1986 sleep-laboratory study is the only one to split its population, and it split it two ways. Eighteen chronic psychophysiological insomniacs were divided into a middle-aged group (29–59) and an older group (60–83), and received six infusions of 30 nmol/kg over a week with a further week of follow-up. The middle-aged group’s sleep reached normal values by the end of the treatment week and stayed there. The older group began with a sleep disturbance twice as severe; their immediate response was larger, but they were not fully normal until the end of the follow-up week. A regression analysis found “clear evidence that the effects of DSIP were correlated to the degree of sleep disturbance”: the worse the sleep, the larger the effect. By the end of the study the whole sample slept normally (PMID 3792404).

Two other groups are informative by contrast. Healthy volunteers with normal sleep got sleepier during the day after a morning dose and slept somewhat better that night (PMID 6895513), which is a smaller effect than the insomniacs showed and consistent with the severity finding. And the 1983 summary’s “complete normalization of disturbed sleep” came after four consecutive injections, not one (PMID 6689058). If the trials are taken at face value, emideltide’s effect was largest in the people whose sleep was worst, small in people who slept fine, and cumulative over a week. That is also, as it happens, the profile that would make a single-night trial by a healthy biohacker come up empty.

The Daytime Half of the Story

Chronic insomnia is a 24-hour condition, and the Basel trials treated it as one. The 1983 summary reported that “during the active awake state, DSIP induced higher alertness and better performance,” and that psychological testing and evaluation by psychotherapists “indicated modulation of ego functions by DSIP in the direction of improved stress tolerance and coping ability” (PMID 6689058). The 1987 placebo-controlled trial tested daytime psychological state and mental performance before and after six injections and found alertness and performance “increased significantly,” with daytime rest, as well as night sleep, reaching normal-control levels (PMID 3622582). Kaeser’s seven patients improved in mood and daytime performance alongside their sleep (PMID 6391926). The first volunteer study had already established the absence of “sedation in the classic pharmacologic way” (PMID 6895513).

This is the part of the record that distinguishes emideltide from a sedative, and it is also the part that explains the most striking adverse report in the user literature. A compound that raises alertness in the waking state, given an hour before bed by someone who is not yet in the second hour, can produce a wired hour rather than a drowsy one. The trials describe that first hour; the users describe it too.

Delayed Sleep Phase, Narcolepsy and a Brain-Stem Injury

Three single-patient reports round out the human sleep record, and each points at a circadian rather than a sedative mechanism. A 47-year-old woman with chronic delayed-sleep-phase insomnia and low-dose benzodiazepine dependence was treated as an inpatient for one week under polygraphic control; her main sleep phase advanced by five hours, she stopped flunitrazepam abruptly and completely, her sleep profile normalized, and actigraphy in the following week confirmed the result held (PMID 3582201). A 35-year-old man with narcolepsy given repeated injections had fewer sleep attacks and more daytime alertness and performance, with his night sleep compressed and REM enhanced; the investigators attributed the effect to “an accentuation of circadian and ultradian rhythms” (PMID 6548968). And a patient with severe insomnia after brain-stem lesions, sleeping under four hours with a high REM ratio, slept longer and better after slow DSIP injection, reversibly, in a pharmacological study that compared it with several other agents (PMID 6198141).

Case reports prove nothing about a population, and none of these was replicated. But the delayed-sleep-phase case is worth holding on to for a specific reason: the user who wrote that their testosterone clinic had started offering DSIP while they were on a prescription benzodiazepine they wanted to stop (r/PeptideForum) was describing, thirty-eight years later, the exact situation of the 1987 patient, minus the sleep laboratory, the polygraph and the physician.

The Case Against: Why Independent Trials Disagreed

Two placebo-controlled trials outside Basel are the reason emideltide never became a drug. In Uruguay, chronic insomniacs received 25 nmol/kg intravenously for four nights in a double-blind crossover with polysomnography. Their awakenings, NREM latency, total waking time and waking after sleep onset all decreased on the peptide, but “no significant differences were found in comparison to baseline or to double-blind placebo nights.” Total and NREM sleep rose, but through stage 2, and the difference from placebo was already present at baseline; slow-wave sleep and REM did not change. The conclusion: “sleep improvement under DSIP treatment is of little clinical significance” (PMID 3583493). In the Netherlands, sixteen chronic insomniacs slept five nights in the laboratory and received the same dose or a glucose placebo on three afternoons in a matched-pairs design. Sleep efficiency was higher and latency shorter on the peptide, and one tiredness measure fell, but the authors found the significant effects “weak and in part could be due to an incidental change in the placebo group,” subjective sleep quality did not change, and short-term treatment was judged “not likely to be of major therapeutic benefit” (PMID 1299794).

The reviews followed the independent data. Steiger and Holsboer’s 1997 survey of neuropeptides and human sleep placed DSIP among compounds whose “impact on human sleep regulation is not yet clear” (PMID 9456470), and Kovalzon and Strekalova’s 2006 review, written by researchers who had spent decades on the molecule, concluded that the link between DSIP and sleep “has never been further characterized” and that DSIP itself, as opposed to its analogues, had not promoted slow-wave sleep in their rabbits and rats (PMID 16539679). There are respectable defences of the Basel results: they used consecutive nightly dosing in severe insomniacs, the independent trials used three or four doses, and the 1986 severity finding predicts smaller effects in milder patients. But those defences were never tested in a trial big enough to settle the matter, and after 1992 nobody tried.

DID YOU KNOW

The last human sleep trial of emideltide was published in 1992. Everything the research market says about it for sleep rests on studies that are between thirty-four and forty-five years old, involving, in total, a few dozen insomniacs. The compound’s most recent human data, a 2009 anaesthesia trial, found it paradoxically reduced delta EEG activity and lightened anaesthesia (PMID 19142086).

The Paradox of the Body’s Own DSIP

If emideltide were the body’s sleep signal, its blood level would be expected to rise at bedtime or ahead of deep sleep. It does the opposite. In twelve healthy volunteers sampled every half hour for 24 hours with simultaneous polysomnography, plasma DSIP-like immunoreactivity peaked at 3 p.m., reached its minimum at 1 a.m., was significantly lower during REM (P < 0.005) and somewhat lower during slow-wave sleep (P < 0.05) than during wakefulness, and “did not rise before, during, or after a significant percentage of episodes of SWS”; instead it tracked body temperature closely (r² = 0.66). The authors concluded that “endogenous elevations of circulating DSIP may be associated with suppression of slow wave and rapid eye movement sleep” (PMID 8175965). A second group found plasma levels fall at the transition from wakefulness to sleep, whether that transition happened at 11 p.m. or, after a night of deprivation, at 5 a.m. (PMID 8745061). In patients with Cushing syndrome, who spend 5.8 percent of the night in delta sleep against 14 percent in controls, morning DSIP was lower than normal, and the correlation between DSIP and delta sleep ran negative, which the authors noted was “against the notion of a causal relationship” (PMID 7700506).

There is one finding on the other side. In fifteen drug-free men with schizophrenia, cerebrospinal-fluid DSIP correlated positively with stage 3 and delta sleep in the first non-REM period of the previous night, the first report of such a relationship in humans, with the authors cautioning that whether it generalized to non-psychiatric sleep “awaits further study” (PMID 1475566). It never got it. What the plasma studies mean for someone injecting the synthetic peptide is not obvious; a pharmacological dose is not a physiological rhythm. But they are a reason to distrust the story in which DSIP is “what your body uses to enter deep sleep,” because the body’s own DSIP does not behave that way.

Injection vs Nasal Spray: What Exists for Each

Every controlled human sleep study of emideltide used slow intravenous infusion. The research market sells two other things: a lyophilized vial for subcutaneous injection, and a pre-mixed nasal spray. Neither has a controlled human sleep trial. What exists for the nasal route comes from Russian-made preparations studied in Ukraine and Russia for other endpoints. An intranasal product called Deltalicin, given at 300 µg a day for two months to thirty insulin-dependent diabetics, shortened the recovery of retinal evoked potentials after a light stress from 137 to 95 seconds (PMID 25739189, PMID 25581971). A related preparation, Deltaran, given for 60 days to eleven elderly diabetics in a Russian pilot, produced improvements on a geriatric rating scale in recent memory, mood, emotional lability and anxiety, and an improvement in sleep quality (p = 0.010), alongside a fall in growth hormone (PMID 15754961). That single sleep-quality item, in eleven diabetic patients with no placebo group, is the entire human evidence base for nasal emideltide and sleep. A 2001 letter reported that intranasal DSIP increased the P300 evoked potential, a cognitive measure (PMID 11763019).

The pharmacology sets the boundaries. Emideltide is degraded rapidly in blood (PMID 3628078) and in cerebrospinal fluid (PMID 2322270), and in a human intestinal cell model 92 percent of it was destroyed within two hours with none crossing the barrier (PMID 8689946), so oral products cannot deliver it. Whether an 849-dalton peptide crosses the nasal mucosa in meaningful amounts is argued at length in the forums; our DSIP nasal spray page covers what the sprays on the market contain and the molecular-weight case for and against. Subcutaneous injection has no human data of any kind. It is worth saying plainly: the route almost everyone uses is the route no study has tested.

What the Trials Administered

Peptide Insider does not recommend doses for any compound. The table below exists because the trials reported what they gave, and a reader deserves the reference point when a vendor listing implies a research-market amount is “the studied dose.” The conversion from nanomoles to micrograms uses the published molecular weight of 849 (PMID 6145137) and is our arithmetic.

Setting Reported administration Equivalent for a 70 kg adult (our calculation) Source
Volunteer and insomnia trials, 1981–1992 25 nmol/kg, slow intravenous infusion, once daily ≈ 21 µg/kg ≈ 1.5 mg, intravenously 6895513, 1299794
Sleep-laboratory week, 1986 30 nmol/kg intravenously, six times in one week ≈ 25 µg/kg ≈ 1.8 mg per infusion 3792404
Endocrine study, 1993 25 µg/kg intravenously over 30 minutes ≈ 1.75 mg 8475226
Anaesthesia trial, 2009 25, 50 or 100 nmol/kg intravenous bolus ≈ 1.5, 3 or 6 mg 19142086
Intranasal diabetic-retinopathy study, 2014 300 µg intranasally, daily, two months 0.3 mg per day, nasal 25739189

Two observations follow from the table, neither of them a recommendation. The trial amounts were an order of magnitude larger than the 100–500 mcg users describe injecting subcutaneously, and they were given intravenously, a route that delivers all of the peptide to the blood at once, where the trials themselves found it is rapidly degraded. Whether a subcutaneous fraction of that amount reaches anything is unknown, because nobody measured it. Our peptide calculator converts a vial’s stated contents into syringe units after reconstitution; it does not suggest an amount, and neither do we.

What Users Report: Self-Reported Effects From Reddit

We searched Reddit on September 9, 2026 for DSIP, emideltide and delta sleep-inducing peptide, screened 488 posts, read the full comment threads of 24 and the posts of a further dozen, across r/Peptides, r/Peptidesource, r/Biohackers, r/Biohacking, r/BodyHackGuide, r/BiohackingU, r/sleep, r/sleephackers, r/USPeptides and r/PeptideForum, dated 2021 to September 2026. Everything below is paraphrased and linked, uses no usernames, describes products nobody verified, and reports amounts only as posters described them. Almost every poster was also using other compounds, most often a GLP-1 receptor agonist or a growth-hormone secretagogue, and several took up DSIP specifically because those compounds had wrecked their sleep, which means the GLP-1 is as likely an explanation for any change as the DSIP.

Tracker-measured gains. The positive reports come with numbers from consumer sleep trackers. One poster reported deep and REM sleep each up by about 40 minutes on the first night (r/Peptides). Another, by night four, had the highest deep and REM figures they had ever recorded, adding that tracker accuracy should be taken “with a grain of salt” (r/Peptides). A third described a “huge improvement in sleep quality” after raising the amount from what they called 300 to 400 mcg (r/sleep). A first-night report from September 2026 “looks promising” (r/Peptides). One poster with mild sleep apnea wrote that DSIP had “basically fixed” it for a month (r/sleephackers). A poster who had slept three to five hours a night for six months after alcohol withdrawal credited adding DSIP with the improvement (r/BodyHackGuide), the one report that maps onto an indication the trials actually studied. Another wrote that DSIP transformed their sleep, but not in the way they expected and only after they nearly quit early, and urged patience (r/BodyHackGuide).

Not every tracker agreed with its owner. One poster felt knocked out while their band showed no more deep or REM sleep than a normal night, and still woke between 3 and 4 a.m. (r/Biohackers); another’s watch showed the same 45 minutes of delta sleep with or without it, with only the dreams changing (r/Biohacking); a third got two hours of deep sleep on the first night and nothing after (r/Peptides). The most-upvoted comment in a 2024 thread described not sleeping more but waking after six hours feeling as if it had been twelve, with none of the usual sleep inertia (r/Biohackers), which is a fair paraphrase of the 1987 trial’s daytime findings.

No effect, from at least as many. A poster who had tried it “several times” at varying amounts and timings, all subcutaneous, from a trusted source, got nothing and called it disappointing (r/Peptides). Another reported DSIP and pinealon had “zero” effect (r/Biohacking). A poster waking every night at 3 a.m. had tried epitalon and DSIP without help (r/Biohacking). A long-term on-and-off user called it hit or miss and blamed expectations (r/BodyHackGuide). A 57-year-old lifelong poor sleeper described it as a last resort (r/Peptides). An article-style post was framed around “who it does nothing for” (r/NTNPerformance).

The opposite of sleep. A first-time user who took what they described as 200 mcg an hour before bed did not sleep for the next 38 hours, and replies in the same thread described four nights of worse or no sleep, and sleep that suffered on it and recovered off it (r/Peptidesource). One user said all it did was give them insomnia (r/Peptides); a 31-year-old with sleep-maintenance insomnia slept about four hours on it, though he was not tired the next day (r/Biohackers); another found it worked for a few weeks and then began waking wide awake mid-night (r/BiohackingU). Read against the trials’ first-hour arousal and daytime-alertness findings, these are the most trial-consistent user reports in the set, and they are bad ones.

Fading, tolerance and the amateur bell curve. Long-term users describe the effect wearing off after four or five nights (r/Peptides), tolerance building fast (r/Peptides), an improvement that lasted about a week (r/Peptides), and, in one account, both a higher amount and nightly use taking the effect away, with two or three nights a week working best (r/Peptides). Another tried everything from what they called 50 to 500 mcg and had it work once in twenty attempts (r/BodyHackGuide). The 1984 review’s U-shaped curve and the failed twice-daily schedule are being rediscovered one vial at a time.

Dreams. One poster found the nasal form gave them nightmares and switched to subcutaneous injection at a lower amount, after which sleep and tracker HRV improved (r/Peptides); another titled a review around “Inception-level lucid dreams” (r/USPeptides). The trials’ “slightly more REM” is the closest documented counterpart (PMID 7028502).

The 1983 indication, unsupervised. Several users are reproducing the withdrawal trials at home: one used it while coming off buprenorphine (r/Peptides), one two years into a methadone taper had read the trials and was trying it for destroyed sleep (r/USPeptides), one reported stopping the benzodiazepines they had been overusing for sleep since starting it (r/Biohackers), and a September 2026 post asks about using it on Suboxone or Sublocade (r/Peptides). The trials behind that use were intravenous, open and conducted on a ward.

Context. Several posters started DSIP because retatrutide or another GLP-1 drug had disturbed their sleep (r/BodyHackGuide); one attributed a 28-pound loss and coming off blood-pressure medication to a retatrutide-plus-DSIP stack, outcomes retatrutide produces alone (r/Biohackers). A poster with a prescription benzodiazepine they wanted to stop was offered DSIP by their testosterone clinic (r/PeptideForum). Two asked whether a hazy reconstituted vial was normal (r/Peptidesource, r/Peptides). One Australian’s shipment was seized at the border (r/Peptides).

What this is and is not: a map of what people say happens, weighted toward those who had something to say and who owned a tracker. It is not a rate, not a comparison to placebo, and not a verification of what was in anyone’s vial. The split between “transformed my sleep” and “did nothing” is, almost exactly, the split between the Basel trials and the independent ones, forty years on and at a tenth of the dose by a different route.

Side Effects in Brief

The human trials recorded very little: “no psychologic, physiologic, or biochemical side effects” in the first volunteer study (PMID 6895513), no daytime sedation in insomniacs (PMID 7028502), and, in the largest series of 107 withdrawal patients, good tolerance “aside from headaches reported by a few patients” (PMID 6548969). The measurable physiological effects were a fall in ACTH with cortisol unchanged (PMID 2554357), no change in growth hormone or prolactin (PMID 8475226), and, in the 2009 anaesthesia trial, increased heart rate, decreased heart-rate variability and a lighter anaesthetic (PMID 19142086). Users add vivid dreams and the occasional sleepless night. The full record, including the endocrine claims that failed testing, the bell-shaped dose curve and the populations never studied, is on our emideltide side effects page.

PERSONAL OBSERVATION — PI EDITORIAL

Of all the compounds we have researched for this site, emideltide is the one where the gap between the 1980s abstracts and the 2026 listings is widest, and it runs in an unusual direction. The original investigators were careful: they reported the first-hour arousal, the failure of twice-daily dosing, the week it took elderly patients to respond. The listings drop all of it and add claims about deep sleep, cortisol and growth hormone that the trials either did not make or specifically refuted. If you read one thing before buying a vial, read the 1987 Uruguayan abstract (Monti and colleagues), which is one paragraph long and is the closest thing to a neutral test the compound ever got.

Regulatory Status

Emideltide is not an approved medicine in the United States or, as far as we can find, anywhere else. In July 2026 the FDA’s Pharmacy Compounding Advisory Committee considered adding “Emideltide (DSIP)” to the 503A bulk drug substances list for opioid withdrawal, chronic insomnia and narcolepsy, the three indications the 1983–1987 studies investigated. It was voted down, 6 to 7 with one abstention, the only one of seven peptides at the meeting to be rejected; BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon were recommended (see our full coverage of the vote). The consequence is that emideltide cannot be compounded for patients in the US and remains a research chemical labelled for non-human use. The committee had access to the same evidence summarized on this page. Half of it found the evidence insufficient for chronic insomnia; the other half did not, and the tie-breaker went against.

Frequently Asked Questions

Does emideltide (DSIP) actually improve sleep?

In the discovering group’s trials, slow intravenous infusion shortened sleep onset, reduced awakenings, improved sleep efficiency and normalized disturbed sleep after about four consecutive doses. In two independent double-blind trials the changes were in the same direction but weak or not significant against placebo. No trial of the injected-at-home or nasal forms exists.

Does emideltide increase deep sleep?

Not in the one independent polysomnographic trial that reported it, where slow-wave sleep was unchanged. The positive trials describe normalized sleep structure, less stage 1 and better efficiency rather than a delta-sleep increase, and a 2009 anaesthesia trial found it reduced delta EEG activity. Its name reflects a 1977 hypothesis, not a measured human result.

How long does emideltide take to work?

The trials found a latency of about one hour, with a slight arousing effect in the first hour and sleep effects beginning in the second, and a duration of up to 20 hours. Normalization of disturbed sleep took about four consecutive daily doses in middle-aged insomniacs and up to two weeks in elderly ones.

Does emideltide work as a nasal spray for sleep?

No controlled human sleep study of nasal emideltide exists. The only human nasal data come from Ukrainian and Russian studies in diabetic patients, one of which recorded an improved sleep-quality score in eleven elderly patients with no placebo group. Oral forms cannot work, because the peptide is destroyed in the gut.

What dose of emideltide did the sleep trials use?

Mostly 25 nmol/kg by slow intravenous infusion once daily, and 30 nmol/kg in one week-long study; at a molecular weight of 849 that is roughly 1.5 to 1.8 mg for a 70 kg adult, intravenously. These are the reported study doses by a route and under monitoring that home use does not reproduce, not recommendations. Users describe subcutaneous amounts about a tenth of that, which no study has tested.

Why do some people say emideltide did nothing?

Because for many it apparently does nothing: two independent placebo-controlled trials found little or no clinically meaningful effect, the trials found the effect was largest in the most severe insomniacs and small in normal sleepers, and the effect built over days rather than nights. Unverified product, the untested subcutaneous route and a bell-shaped dose curve add further reasons.

Can emideltide make sleep worse?

The trials recorded a slight arousing effect in the first hour after injection and higher daytime alertness, and one user described 38 hours awake after a first dose. Twice-daily dosing lost the effect in the 1984 studies. Vivid dreams and, with the nasal form in one account, nightmares are reported by users.

Is emideltide better than melatonin or prescription sleep aids?

No head-to-head trial exists. The only comparison in the literature is a single 1984 case in which DSIP was compared with several other agents in one brain-stem-injury patient. The trials do describe something sedatives do not: no next-day sedation and improved daytime alertness.

Is emideltide safe?

In roughly a dozen human studies it was tolerated well, with headache in a few withdrawal patients the only named side effect, no dependence and no rebound insomnia at three to seven months. It did raise heart rate and lower heart-rate variability in the one trial that measured them, and it has never been studied in pregnancy, in children, in heart disease or in combination with the compounds users stack it with.

Why did the FDA committee vote against emideltide?

The July 2026 Pharmacy Compounding Advisory Committee vote on adding it to the 503A list for opioid withdrawal, chronic insomnia and narcolepsy failed 6 to 7 with one abstention. The evidence for those uses is small, old and split between positive results from the discovering group and negative independent trials.

Glossary of Terms

  • Emideltide: the International Nonproprietary Name for delta sleep-inducing peptide (DSIP), a nine-amino-acid peptide isolated in 1977.
  • Polysomnography: laboratory sleep recording combining EEG, eye movement and muscle activity to score sleep stages; the measurement behind every trial on this page.
  • Sleep efficiency: time asleep as a percentage of time in bed; the measure that most consistently improved in the trials.
  • Sleep onset latency: time from lights-out to sleep; shortened in several trials, non-significantly in the independent ones.
  • Slow-wave sleep (delta sleep): stages 3 and 4 of non-REM sleep, marked by slow EEG waves; unchanged in the independent trial that measured it.
  • REM sleep: the dreaming stage; “slightly more” in insomniacs given DSIP, which may relate to users’ dream reports.
  • Psychophysiological insomnia: chronic insomnia maintained by conditioned arousal rather than a medical cause; the diagnosis in the Basel trials.
  • Delayed sleep phase: a circadian disorder in which the sleep period is shifted late; advanced by five hours in one DSIP case report.
  • nmol/kg: nanomoles per kilogram of body weight; the unit the trials used, convertible to micrograms with the molecular weight of 849.
  • Bell-shaped dose curve: an effect that peaks at an intermediate dose and falls at higher ones; documented for DSIP in animals and suggested by the failure of twice-daily dosing in humans.

References

  1. Schneider-Helmert D, Gnirss F, Monnier M, et al. Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior. Int J Clin Pharmacol Ther Toxicol. 1981. PMID 6895513
  2. Schneider-Helmert D, Schoenenberger GA. The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep. Experientia. 1981. PMID 7028502
  3. Synthetic delta-sleep-inducing peptide improves sleep in insomniacs. Lancet. 1981. PMID 6112579
  4. Schneider-Helmert D, Schoenenberger GA. Effects of DSIP in man. Multifunctional psychophysiological properties besides induction of natural sleep. Neuropsychobiology. 1983. PMID 6689058
  5. Schneider-Helmert D. DSIP in insomnia. Eur Neurol. 1984. PMID 6391925
  6. Kaeser HE. A clinical trial with DSIP. Eur Neurol. 1984. PMID 6391926
  7. Schneider-Helmert D. Effects of DSIP on narcolepsy. Eur Neurol. 1984. PMID 6548968
  8. Sleep disturbances in a case of brain-stem lesions; pharmacological study. Electroencephalogr Clin Neurophysiol. 1984. PMID 6198141
  9. Graf MV, Kastin AJ. Delta-sleep-inducing peptide (DSIP): a review. Neurosci Biobehav Rev. 1984. PMID 6145137
  10. Scherschlicht R, Aeppli L, Polc P, et al. Some pharmacological effects of delta-sleep-inducing peptide (DSIP). Eur Neurol. 1984. PMID 6548967
  11. Dick P, Costa C, Fayolle K, et al. DSIP in the treatment of withdrawal syndromes from alcohol and opiates. Eur Neurol. 1984. PMID 6548969
  12. Schneider-Helmert D. Efficacy of DSIP to normalize sleep in middle-aged and elderly chronic insomniacs. Eur Neurol. 1986. PMID 3792404
  13. Schneider-Helmert D. Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia. Eur Neurol. 1987. PMID 3622582
  14. Monti JM, Debellis J, Alterwain P, et al. Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs. Int J Clin Pharmacol Res. 1987. PMID 3583493
  15. Schneider-Helmert D, Hermann E, Schoenenberger GA. [The use of DSIP (delta sleep-inducing peptide) in the correction of phase-shifted insomnia]. Dtsch Med Wochenschr. 1987. PMID 3582201
  16. Graf MV, Saegesser B, Schoenenberger GA. Degradation and aggregation of delta sleep-inducing peptide (DSIP) and two analogs in plasma and serum. Peptides. 1987. PMID 3628078
  17. Bjartell A, Ekman R, Bergquist S, et al. Reduction of immunoreactive ACTH in plasma following intravenous injection of delta sleep-inducing peptide in man. Psychoneuroendocrinology. 1989. PMID 2554357
  18. Nyberg F, Thörnwall M, Hetta J. Aminopeptidase in human CSF which degrades delta-sleep inducing peptide (DSIP). Biochem Biophys Res Commun. 1990. PMID 2322270
  19. Bes F, Hofman W, Schuur J, Van Boxtel C. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. Neuropsychobiology. 1992. PMID 1299794
  20. Delta sleep-inducing-peptide-like immunoreactivity (DSIP-LI) and delta sleep in schizophrenic volunteers. Sleep. 1992. PMID 1475566
  21. Giusti M, Carraro A, Porcella E, et al. Delta sleep-inducing peptide administration does not influence growth hormone and prolactin secretion in normal women. Psychoneuroendocrinology. 1993. PMID 8475226
  22. Friedman TC, Garcia-Borreguero D, Hardwick D, et al. Diurnal rhythm of plasma delta-sleep-inducing peptide in humans: evidence for positive correlation with body temperature and negative correlation with rapid eye movement and slow wave sleep. J Clin Endocrinol Metab. 1994. PMID 8175965
  23. Friedman TC, García-Borreguero D, Hardwick D, et al. Decreased delta-sleep and plasma delta-sleep-inducing peptide in patients with Cushing syndrome. Neuroendocrinology. 1994. PMID 7700506
  24. Seifritz E, Müller MJ, Schönenberger GA, et al. Human plasma DSIP decreases at the initiation of sleep at different circadian times. Peptides. 1995. PMID 8745061
  25. Augustijns PF, Borchardt RT. Transport and metabolism of delta sleep-inducing peptide in cultured human intestinal epithelial cell monolayers. Drug Metab Dispos. 1995. PMID 8689946
  26. Steiger A, Holsboer F. Neuropeptides and human sleep. Sleep. 1997. PMID 9456470
  27. Hruz P, Zechner S, Heimberg D, et al. Intranasal administration of delta sleep-inducing peptide increases P300. J Clin Psychopharmacol. 2001. PMID 11763019
  28. Obál F Jr, Krueger JM. Biochemical regulation of non-rapid-eye-movement sleep. Front Biosci. 2003. PMID 12700031
  29. Odin VI, Belikova TV, Pushkova ES, et al. [Diabetes mellitus in elderly: geroprotective and antidiabetic properties of delta-sleep induced peptide]. Adv Gerontol. 2004. PMID 15754961
  30. Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. J Neurochem. 2006. PMID 16539679
  31. Pomfrett CJ, Dolling S, Anders NR, et al. Delta sleep-inducing peptide alters bispectral index, the electroencephalogram and heart rate variability when used as an adjunct to isoflurane anaesthesia. Eur J Anaesthesiol. 2009. PMID 19142086
  32. Kresiun NV, Godlevskii LS. [Using deltalicin for the treatment of patients with diabetic retinopathy]. Eksp Klin Farmakol. 2014. PMID 25739189
  33. Kresyun NV. The influence of deltalycyn and transcranial cerebellar stimulation upon recovery of retina after photo stress in patients with diabetic retinopathy. Rev Med Chir Soc Med Nat Iasi. 2014. PMID 25581971
  34. Peptide Insider. FDA Peptide Vote 2026: What the Committee Decided. August 4, 2026. peptideinsider.org
  35. Reddit threads cited inline were read on September 9, 2026; the search and thread log is kept in our editorial records.